About: http://data.cimple.eu/news-article/08c982fbb9086dd26892e510bd19187666f2f02e5b51c497ab806735

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/08c982fbb9086dd26892e510bd19187666f2f02e5b51c497ab806735 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	A study performed in New York hospitals found no evidence of either harm or benefit from giving the malaria drug hydroxychloroquine to severely ill coronavirus patients. "The risk of intubation or death was not significantly higher or lower among patients who received hydroxychloroquine than among those who did not," the authors of the study said. They said the study, published on Thursday in The New England Journal of Medicine, "should not be taken to rule out either benefit or harm of hydroxychloroquine treatment." "However, our findings do not support the use of hydroxychloroquine at present, outside randomized clinical trials testing its efficacy," they said. US President Donald Trump has frequently touted the use of hydroxychloroquine as a treatment for coronavirus patients. Hydroxychloroquine and a related compound chloroquine have been used for decades to treat malaria, as well as the autoimmune disorders lupus and rheumatoid arthritis. The observational study was conducted among emergency room patients at the New York-Presbyterian Hospital and Columbia University Irving Medical Center and funded by the National Institutes of Health. For the study, 811 patients received two doses of 600 mg of hydroxychloroquine on the first day and 400 mg daily for four days. Another 565 patients did not receive the drug. Comparing the two groups, "there was no significant association between hydroxychloroquine use and intubation or death," the study said. Health Canada, the European Medicines Agency and the US Food and Drug Administration have warned against the use of hydroxychloroquine to treat COVID-19 outside of clinical trials. US regulators last week authorized the emergency use of the experimental drug remdesivir against COVID-19 after it was shown in a major clinical trial to shorten the time to recovery in some coronavirus patients. cl/to
schema:headline	No apparent harm or benefit from hydroxychloroquine: study
schema:mentions	Health Canada Antimalarial medication Systemic lupus erythematosus Autoimmune disease European Medicines Agency Clinical trial New England Remdesivir Chloroquine Hydroxychloroquine New York City Severe acute respiratory syndrome coronavirus 2 President of the United States Donald Trump NewYork–Presbyterian Hospital Columbia University Medical Center Intubation Observational study Rheumatoid arthritis
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-05-07 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	82 (xsd:integer)
http://data.cimple...entionsConspiracy	suppressed cures conspiracy theory

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software